Individuals with depression, on common, die prematurely, have excessive ranges of bodily comorbidities and might expertise accelerated organic ageing. A larger understanding of age-related changes in physiology might present novel organic insights that will assist inform methods to mitigate extra mortality in depression. We used generalised additive fashions to look at age-related changes in 15 cardiovascular, body composition, grip strength and lung operate measures, evaluating males and females with a lifetime historical past of depression to wholesome controls.
The important dataset included 342,393 adults (imply age = 55.87 years, SD = 8.09; 52.61% females). We discovered statistically important case-control variations for many physiological measures. There was some proof that age-related changes in body composition, cardiovascular operate, lung operate and heel bone mineral density adopted totally different trajectories in depression.
These variations didn’t uniformly slender or widen with age and differed by intercourse. For instance, BMI in feminine instances was 1.1 kg/m2 larger at age 40 and this distinction narrowed to 0.four kg/m2 at age 70. In males, systolic blood strain was 1 mmHg decrease in depression instances at age 45 and this distinction widened to 2.5 mmHg at age 65. These findings counsel that focused screening for physiological operate in middle-aged and older adults with depression is warranted to probably mitigate extra mortality.
Can an information pushed weight problems classification system establish these susceptible to extreme COVID-19 in the UK Biobank cohort research?
COVID-19 is a illness that has been proven to have outcomes that fluctuate by sure socio-demographic and socio-economic teams. It is more and more vital that an understanding of those outcomes ought to be derived not from the consideration of 1 facet, however by a extra multi-faceted understanding of the particular person. In this research use is fabricated from a latest weight problems pushed classification of contributors in the United Kingdom Biobank (UKB) to establish traits in COVID-19 outcomes.
This classification is knowledgeable by a lately created weight problems methods map, and the COVID-19 outcomes are: endeavor a take a look at, a optimistic take a look at, hospitalisation and mortality. It is demonstrated that the classification is ready to establish significant differentials in these outcomes. This extra holistic strategy is advisable for identification and prioritisation of COVID-19 threat and attainable long-COVID willpower.
Whole-exome imputation inside UK Biobank powers uncommon coding variant affiliation and fine-mapping analyses
Exome affiliation research thus far have typically been underpowered to systematically consider the phenotypic affect of very uncommon coding variants. We leveraged in depth haplotype sharing between 49,960 exome-sequenced UK Biobank contributors and the the rest of the cohort (complete n ≈ 500,000) to impute exome-wide variants with accuracy R2 > 0.5 all the way down to minor allele frequency (MAF) ~0.00005.
Association and fine-mapping analyses of 54 quantitative traits recognized 1,189 important associations (P < 5 × 10-8) involving 675 distinct uncommon protein-altering variants (MAF < 0.01) that handed stringent filters for seemingly causality.
Across all traits, 49% of associations (578/1,189) occurred in genes with two or extra hits; follow-up analyses of those genes recognized allelic collection containing as much as 45 distinct ‘likely-causal’ variants. Our outcomes exhibit the utility of within-cohort imputation in population-scale genome-wide affiliation research, present a catalog of likely-causal, large-effect coding variant associations and foreshadow the insights that shall be revealed as genetic biobank research proceed to develop.
The governance of genomic biobank analysis in Africa: reframing the regulatory tilt
Genomic biobank analysis has skilled exponential progress in latest years. It represents an actual alternative to treatment international well being inequity that has seen restricted funding in ailments affecting populations from low- and middle-income international locations. Previous analysis in Africa was restricted to so-called parachute analysis, whereby samples had been taken from native populations to be used in high-income international locations with no native oversight or use of the pattern.
These exploitative practices have to be guarded towards, however the present regulation of genomic analysis in Africa adopts a precautionary strategy that at instances is restrictive in nature. We argue that the regulation and oversight of genomic biobank analysis ought to guard towards exploitative analysis, however in a fashion that promotes reciprocal profit and not restrictive analysis practices. To obtain this, there have to be a rebalancing of the regulatory tilt.
The biobank of barretos most cancers hospital: 14 years of expertise in most cancers analysis
Despite the developments in most cancers analysis over years, most cancers remains to be considered one of the main causes of loss of life worldwide. In Brazil, the variety of most cancers instances for the a number of subsequent years (2020-2022) is predicted to extend as much as 625,000. Thus, translational analysis has been important to find out the potential threat, prognostic, and predictive biomarkers in most cancers. Therefore, Barretos Cancer Hospital applied a biobank (BB-BCH) in 2006, which is liable for processing, storage, and provision of organic supplies from most cancers and non-cancer contributors.
Hence, this text aimed to explain BB-BCH’s historical past, experiences, and outcomes and discover its affect on Brazilian translational oncology analysis state of affairs. BB-BCH has a multidisciplinary group who’re liable for guaranteeing the high quality of all processes as advisable by worldwide pointers for biobanks. Furthermore, BB-BCH has ample gear to make sure the high quality of all materials requested by researchers as genetic materials (DNA and RNA) and/or total biospecimens.
Human Transforming Growth Factor Beta 1 (TGF-b1) CLIA Kit |
|||
| abx196293-96tests | Abbexa | 96 tests | 825 EUR |
Human Transforming growth factor beta 1 (TGF-b1) ELISA Kit |
|||
| LF-EK60028 | Abfrontier | 1×96T | 790 EUR |
TGF |
|||
| ABD8749 | Lifescience Market | 100 ug | 438 EUR |
TGF |
|||
| ABF5347 | Lifescience Market | 100 ug | 438 EUR |
TGF- |
|||
| EF018074 | Lifescience Market | 96 Tests | 689 EUR |
TGF- |
|||
| EF019518 | Lifescience Market | 96 Tests | 689 EUR |
TGF- |
|||
| EF016694 | Lifescience Market | 96 Tests | 689 EUR |
TGF |
|||
| EF016747 | Lifescience Market | 96 Tests | 689 EUR |
TGF- |
|||
| EF016878 | Lifescience Market | 96 Tests | 689 EUR |
TGF- |
|||
| EF017053 | Lifescience Market | 96 Tests | 689 EUR |
TGF- |
|||
| EF017054 | Lifescience Market | 96 Tests | 689 EUR |
TGF- |
|||
| EF017076 | Lifescience Market | 96 Tests | 689 EUR |
TGF- |
|||
| EF010976 | Lifescience Market | 96 Tests | 689 EUR |
TGF- |
|||
| EF012749 | Lifescience Market | 96 Tests | 689 EUR |
TGF- |
|||
| EF012916 | Lifescience Market | 96 Tests | 689 EUR |
TGF- |
|||
| EF012917 | Lifescience Market | 96 Tests | 689 EUR |
TGF- |
|||
| EF012918 | Lifescience Market | 96 Tests | 689 EUR |
TGF |
|||
| EF000223 | Lifescience Market | 96 Tests | 689 EUR |
TGF |
|||
| EF000225 | Lifescience Market | 96 Tests | 689 EUR |
TGF |
|||
| EF000226 | Lifescience Market | 96 Tests | 689 EUR |
TGF |
|||
| EF000227 | Lifescience Market | 96 Tests | 689 EUR |
TGF |
|||
| ABF8080 | Lifescience Market | 100 ug | 438 EUR |
TGF |
|||
| ABF8081 | Lifescience Market | 100 ug | 438 EUR |
Protein B1 (B1) Antibody |
|||
| 20-abx317795 | Abbexa |
|
|
TGF beta |
|||
| MO20012 | Neuromics | 100 ul. | 246 EUR |
TGF Beta1 |
|||
| PR15009 | Neuromics | 1 ug | 376 EUR |
TGF Beta1 |
|||
| PR27106 | Neuromics | 2 ug | 257 EUR |
TGF Beta3 |
|||
| PR27164 | Neuromics | 2 ug | 191 EUR |
TGF Beta2 |
|||
| PR27165 | Neuromics | 5 ug | 318 EUR |
TGF-beta3 |
|||
| GT15074 | Neuromics | 100 ug | 526 EUR |
Protein B1 (B1) Antibody (HRP) |
|||
| 20-abx317796 | Abbexa |
|
|
Protein B1 (B1) Antibody (FITC) |
|||
| 20-abx317797 | Abbexa |
|
|
Protein B1 (B1) Antibody (Biotin) |
|||
| 20-abx317798 | Abbexa |
|
|
Ephrin B1 (Ephrin B1) Antibody |
|||
| abx232810-100ug | Abbexa | 100 ug | 481 EUR |
TGF-Alpha/ Rat TGF- Alpha ELISA Kit |
|||
| ELA-E0123r | Lifescience Market | 96 Tests | 886 EUR |
TGF-Beta1/ Rat TGF- Beta1 ELISA Kit |
|||
| ELA-E0124r | Lifescience Market | 96 Tests | 886 EUR |
TGF-Beta/ Rat TGF- Beta ELISA Kit |
|||
| ELA-E1949r | Lifescience Market | 96 Tests | 886 EUR |
Bovine Insulin ELISA Kit, 96 tests, Quantitative, 96 tests |
|||
| 0030-10-B1 | Alpha Diagnostics | 1 kit | 651 EUR |
B1 Antibody |
|||
| 1-CSB-PA882501LA01HKA | Cusabio |
|
|
|
Description: A polyclonal antibody against B1. Recognizes B1 from Human herpesvirus 6B. This antibody is Unconjugated. Tested in the following application: ELISA, WB; Recommended dilution: WB:1:500-1:5000 |
|||
Avermectin B1 |
|||
| HY-15311 | MedChemExpress | 100mg | 121 EUR |
Fumonisin B1 |
|||
| F030-0.5MG | TOKU-E | 0.5 mg | 154 EUR |
Fumonisin B1 |
|||
| F030-2.5MG | TOKU-E | 2.5 mg | 465 EUR |
Nafocare B1 |
|||
| HY-100241 | MedChemExpress | 10mg | 3730 EUR |
Saikosaponin B1 |
|||
| HY-N0247 | MedChemExpress | 10mg | 398 EUR |
Procyanidin B1 |
|||
| HY-N0795 | MedChemExpress | 10mg | 1359 EUR |
Jionoside B1 |
|||
| HY-N2218 | MedChemExpress | 5mg | 509 EUR |
Aflatoxin B1 |
|||
| HY-N6615 | MedChemExpress | 10mM/1mL | 311 EUR |
Fumonisin B1 |
|||
| HY-N6719 | MedChemExpress | 1mg | 302 EUR |
Coxsackievirus (B1) |
|||
| DAG4690 | Creative Diagnostics | 0.25 mg | Ask for price |
Enniatin B1 |
|||
| E038-1MG | TOKU-E | 1 mg | 224 EUR |
Enniatin B1 |
|||
| E038-5MG | TOKU-E | 5 mg | 708 EUR |
Bafilomycin B1 |
|||
| GA8347-100UG | Glentham Life Sciences | 100 ug | 114 EUR |
Bafilomycin B1 |
|||
| GA8347-1MG | Glentham Life Sciences | 1 mg | 166 EUR |
Bafilomycin B1 |
|||
| GA8347-5MG | Glentham Life Sciences | 5 mg | 355 EUR |
Ephrin B1 |
|||
| PR27094 | Neuromics | 5 ug | 191 EUR |
Saquayamycin B1 |
|||
| GL5222-1MG | Glentham Life Sciences | 1 mg | 229 EUR |
Saquayamycin B1 |
|||
| GL5222-500UG | Glentham Life Sciences | 500 ug | 172 EUR |
Saquayamycin B1 |
|||
| GL5222-5MG | Glentham Life Sciences | 5 mg | 551 EUR |
Bafilomycin B1 |
|||
| B039-1MG | TOKU-E | 1 mg | 157 EUR |
Bafilomycin B1 |
|||
| B039-5MG | TOKU-E | 5 mg | 473 EUR |
Fumonisin B1 |
|||
| 20-abx076560 | Abbexa |
|
|
Aflatoxin B1 |
|||
| A115-1MG | TOKU-E | 1 mg | 119 EUR |
Aflatoxin B1 |
|||
| A115-5MG | TOKU-E | 5 mg | 342 EUR |
Polymyxin B1 |
|||
| C3598-1 | ApexBio | 1 mg | 186 EUR |
|
Description: Polymyxin B1 can bind and kill Gram-negative bacteria.In view of the emergence of multidrug resistance among Gram-negative bacteria, polymyxin B has emerged as one of the therapeutic agents of last resort. |
|||
Polymyxin B1 |
|||
| C3598-10 | ApexBio | 10 mg | 920 EUR |
|
Description: Polymyxin B1 can bind and kill Gram-negative bacteria.In view of the emergence of multidrug resistance among Gram-negative bacteria, polymyxin B has emerged as one of the therapeutic agents of last resort. |
|||
Polymyxin B1 |
|||
| C3598-5 | ApexBio | 5 mg | 595 EUR |
|
Description: Polymyxin B1 can bind and kill Gram-negative bacteria.In view of the emergence of multidrug resistance among Gram-negative bacteria, polymyxin B has emerged as one of the therapeutic agents of last resort. |
|||
Demethylasterriquinone B1 |
|||
| B6869-1 | ApexBio | 1 mg | 126 EUR |
Demethylasterriquinone B1 |
|||
| B6869-5 | ApexBio | 5 mg | 348 EUR |
Proanthocyanidin B1 |
|||
| N2180-5 | ApexBio | 5 mg | 572 EUR |
|
Description: Extracted from Betula pubescens Ehrh. hypophloedes;Store the product in sealed, cool and dry condition |
|||
Fumonisin B1 |
|||
| A4537-1 | ApexBio | 1 mg | 132 EUR |
|
Description: Mycotoxin produced by Fusarium moniliforme. Potently inhibits sphingosine N-acyltransferase (ceramide synthase), causing an accumulation of sphingoid bases (IC50 ~ 75 nM). |
|||
Fumonisin B1 |
|||
| A4537-10 | ApexBio | 10 mg | 666 EUR |
|
Description: Mycotoxin produced by Fusarium moniliforme. Potently inhibits sphingosine N-acyltransferase (ceramide synthase), causing an accumulation of sphingoid bases (IC50 ~ 75 nM). |
|||
Fumonisin B1 |
|||
| A4537-5 | ApexBio | 5 mg | 419 EUR |
|
Description: Mycotoxin produced by Fusarium moniliforme. Potently inhibits sphingosine N-acyltransferase (ceramide synthase), causing an accumulation of sphingoid bases (IC50 ~ 75 nM). |
|||
Avermectin B1 |
|||
| A3202-100 | ApexBio | 100 mg | 112 EUR |
|
Description: Avermectin B1 (Abamectin) is a widely used insecticide and anthelmintic. Avermectin B1 is a mixture of avermectins containing more than 80% avermectin B1a and less than 20% avermectin B1b. |
|||
Avermectin B1 |
|||
| A3202-1000 | ApexBio | 1 g | 144 EUR |
|
Description: Avermectin B1 (Abamectin) is a widely used insecticide and anthelmintic. Avermectin B1 is a mixture of avermectins containing more than 80% avermectin B1a and less than 20% avermectin B1b. |
|||
Avermectin B1 |
|||
| A3202-10000 | ApexBio | 10 g | 676 EUR |
|
Description: Avermectin B1 (Abamectin) is a widely used insecticide and anthelmintic. Avermectin B1 is a mixture of avermectins containing more than 80% avermectin B1a and less than 20% avermectin B1b. |
|||
Avermectin B1 |
|||
| A3202-5000 | ApexBio | 5 g | 395 EUR |
|
Description: Avermectin B1 (Abamectin) is a widely used insecticide and anthelmintic. Avermectin B1 is a mixture of avermectins containing more than 80% avermectin B1a and less than 20% avermectin B1b. |
|||
Procyanidin B1 |
|||
| TB0698 | ChemNorm | 10mg | 249 EUR |
Jionoside B1 |
|||
| TB0813-0025 | ChemNorm | 10mg | 484 EUR |
Ilexsaponin B1 |
|||
| TBW00086 | ChemNorm | 10mg | 420 EUR |
Aflatoxin B1 |
|||
| TBW00290 | ChemNorm | 1ml | 313 EUR |
Enniatin B1 |
|||
| TBW01226 | ChemNorm | unit | Ask for price |
Cinnamtannin B1 |
|||
| TBW01547 | ChemNorm | unit | Ask for price |
Cylindrol B1 |
|||
| TBZ0224 | ChemNorm | unit | Ask for price |
Tacacoside B1 |
|||
| TBZ0924 | ChemNorm | unit | Ask for price |
Yunganoside B1 |
|||
| TBZ1059 | ChemNorm | unit | Ask for price |
Combretastatin B1 |
|||
| TBZ1177 | ChemNorm | unit | Ask for price |
Meliatoxin B1 |
|||
| TBZ1616 | ChemNorm | unit | Ask for price |
Prostaglandin B1 |
|||
| TBZ1840 | ChemNorm | unit | Ask for price |
Jujuboside B1 |
|||
| TBZ2572 | ChemNorm | 10mg | Ask for price |
Saikosaponin B1 |
|||
| TS054284 | ChemNorm | 20mg | Ask for price |
TGF? Polyclonal Antibody |
|||
| ES8382-100ul | ELK Biotech | 100ul | 279 EUR |
|
Description: A Rabbit Polyclonal antibody against TGF? from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, WB, ELISA |
|||
TGF? Polyclonal Antibody |
|||
| ES8382-50ul | ELK Biotech | 50ul | 207 EUR |
|
Description: A Rabbit Polyclonal antibody against TGF? from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, WB, ELISA |
|||
TGF-beta1, Human |
|||
| HY-P7118 | MedChemExpress | 100ug | 1221 EUR |
TGF-beta2, Human |
|||
| HY-P7119 | MedChemExpress | 50ug | 957 EUR |
TGF-α, Human |
|||
| HY-P7411 | MedChemExpress | 50ug | 234 EUR |
TGF? Polyclonal Antibody |
|||
| ES3593-50ul | ELK Biotech | 50ul | 207 EUR |
|
Description: A Rabbit Polyclonal antibody against TGF? from Human/Mouse/Rat/Monkey. This antibody is tested and validated for WB, ELISA, IHC, WB, ELISA |
|||
TGF? Polyclonal Antibody |
|||
| ES3593-100ul | ELK Biotech | 100ul | 279 EUR |
|
Description: A Rabbit Polyclonal antibody against TGF? from Human/Mouse/Rat/Monkey. This antibody is tested and validated for WB, ELISA, IHC, WB, ELISA |
|||
TGF-alpha, CF |
|||
| PR15016CF | Neuromics | 500 ug | 1342 EUR |
TGF-b Antibody |
|||
| 21678-100ul | SAB | 100ul | 252 EUR |
TGF-b Antibody |
|||
| 21678-50ul | SAB | 50ul | 187 EUR |
TGF β2 Antibody |
|||
| 33497-100ul | SAB | 100ul | 252 EUR |
TGF β2 Antibody |
|||
| 33497-50ul | SAB | 50ul | 187 EUR |
TGF β3 Antibody |
|||
| 33498-100ul | SAB | 100ul | 252 EUR |
TGF β3 Antibody |
|||
| 33498-50ul | SAB | 50ul | 187 EUR |
TGF alpha Antibody |
|||
| 33499-100ul | SAB | 100ul | 252 EUR |
TGF alpha Antibody |
|||
| 33499-50ul | SAB | 50ul | 187 EUR |
TGF alpha Antibody |
|||
| 49822-100ul | SAB | 100ul | 333 EUR |
TGF alpha Antibody |
|||
| 49822-50ul | SAB | 50ul | 239 EUR |
Pro-TGF-a |
|||
| 5-01812 | CHI Scientific | 4 x 5mg | Ask for price |
Human TGF-β3 |
|||
| BJU020 | GroPep | 20 µg | 253 EUR |
Human TGF-β3 |
|||
| BJU100 | GroPep | 100 µg | 346 EUR |
TGF-? (Human) antibody |
|||
| Y240 | Sceti | 50 ul | 427 EUR |
|
Description: The TGF-? (Human) antibody is available in Europe and for worldwide shipping via Gentaur. |
|||
Goat(TGF-β) |
|||
| QY-E140043 | Qayee Biotechnology | 96T | 413 EUR |
TGF beta2 Antibody |
|||
| ABF0260 | Lifescience Market | 100 ug | 438 EUR |
TGF alpha Antibody |
|||
| ABF0262 | Lifescience Market | 100 ug | 438 EUR |
TGF beta1 Antibody |
|||
| ABF1027 | Lifescience Market | 100 ug | 438 EUR |
TGF beta1 Antibody |
|||
| BF0173 | Affbiotech | 200ul | 376 EUR |
|
Description: TGF beta1 antibody detects endogenous levels of total TGF beta1. |
|||
TGF beta antibody |
|||
| 10R-6686 | Fitzgerald | 50 ug | 181 EUR |
|
Description: Rat monoclonal TGF beta antibody |
|||
TGF beta antibody |
|||
| 10R-7765 | Fitzgerald | 500 ug | 565 EUR |
|
Description: Mouse monoclonal TGF beta antibody |
|||
TGF alpha antibody |
|||
| 10R-T120a | Fitzgerald | 100 ug | 500 EUR |
|
Description: Mouse monoclonal TGF alpha antibody |
|||
TGF alpha antibody |
|||
| 20C-CR2026SP | Fitzgerald | 2.5 mg | 374 EUR |
|
Description: Sheep polyclonal TGF alpha antibody |
|||
TGF alpha antibody |
|||
| 70-TG89 | Fitzgerald | 1 mg | 812 EUR |
|
Description: Affinity purified Goat polyclonal TGF alpha antibody |
|||
TGF beta antibody |
|||
| 70-TG90 | Fitzgerald | 1 mg | 789 EUR |
|
Description: Affinity purified Goat polyclonal TGF beta antibody |
|||
TGF alpha antibody |
|||
| 70-TR56 | Fitzgerald | 50 ug | 298 EUR |
|
Description: Affinity purified Rabbit polyclonal TGF alpha antibody |
|||
TGF beta2 Antibody |
|||
| AF0260 | Affbiotech | 200ul | 304 EUR |
|
Description: TGF beta2 Antibody detects endogenous levels of TGF beta2. |
|||
TGF alpha Antibody |
|||
| AF0262 | Affbiotech | 200ul | 304 EUR |
|
Description: TGF alpha antibody detects endogenous levels of total TGF alpha. |
|||
TGF beta1 Antibody |
|||
| AF1027 | Affbiotech | 200ul | 304 EUR |
|
Description: TGF beta1 Antibody detects endogenous levels of total TGF beta protein. |
|||
TGF alpha antibody |
|||
| 70R-30774 | Fitzgerald | 100 ug | 327 EUR |
|
Description: Rabbit polyclonal TGF alpha antibody |
|||
TGF alpha antibody |
|||
| 70R-12318 | Fitzgerald | 100 ug | 403 EUR |
|
Description: Rabbit polyclonal TGF alpha antibody |
|||
TGF beta antibody |
|||
| 70R-12368 | Fitzgerald | 100 ug | 527 EUR |
|
Description: Rabbit polyclonal TGF beta antibody |
|||
TGF alpha antibody |
|||
| 70R-13903 | Fitzgerald | 100 ug | 322 EUR |
|
Description: Affinity purified Sheep polyclonal TGF alpha antibody |
|||
TGF alpha antibody |
|||
| 70R-15427 | Fitzgerald | 100 ug | 327 EUR |
|
Description: Rabbit polyclonal TGF alpha antibody |
|||
TGF alpha antibody |
|||
| 70R-50472 | Fitzgerald | 100 ul | 244 EUR |
|
Description: Purified Polyclonal TGF alpha antibody |
|||
TGF alpha antibody |
|||
| 70R-51342 | Fitzgerald | 100 ul | 244 EUR |
|
Description: Purified Polyclonal TGF alpha antibody |
|||
TGF alpha protein |
|||
| 30R-2357 | Fitzgerald | 20 ug | 224 EUR |
|
Description: Purified recombinant Human TGF alpha protein |
|||
TGF alpha protein |
|||
| 30R-AT002 | Fitzgerald | 20 ug | 133 EUR |
|
Description: Purified recombinant Human TGF alpha protein |
|||
pET-28a-TGF |
|||
| PVTB00118-1a | Lifescience Market | 2 ug | 356 EUR |
anti-TGF alpha |
|||
| YF-PA15003 | Abfrontier | 100 ug | 403 EUR |
|
Description: Rabbit polyclonal to TGF alpha |
|||
TGF-alpha Antibody |
|||
| 5339-100 | Biovision | 316 EUR | |
TGF-alpha Antibody |
|||
| 5339-30T | Biovision | 146 EUR | |
TGF-beta2 Antibody |
|||
| 5340-100 | Biovision | 316 EUR | |
TGF-beta2 Antibody |
|||
| 5340-30T | Biovision | 146 EUR | |
TGF-beta2 Antibody |
|||
| 5343R-100 | Biovision | 316 EUR | |
TGF-beta2 Antibody |
|||
| 5343R-30T | Biovision | 146 EUR | |
TGF-beta3 Antibody |
|||
| 5344R-100 | Biovision | 316 EUR | |
TGF-beta3 Antibody |
|||
| 5344R-30T | Biovision | 146 EUR | |
TGF-?1 Antibody |
|||
| 5559-100 | Biovision | 403 EUR | |
TGF-?1 Antibody |
|||
| 5559-30T | Biovision | 164 EUR | |
anti-TGF alpha |
|||
| YF-PA24840 | Abfrontier | 50 ul | 334 EUR |
|
Description: Mouse polyclonal to TGF alpha |
|||
TGF-尾 ELISA KIT|Mouse TGF-尾 ELISA KIT |
|||
| EF013931 | Lifescience Market | 96 Tests | 689 EUR |
Aflatoxin B1 Standard |
|||
| SD001 | Unibiotest | 0.5ug/mL | 523 EUR |
Fumonisin B1 Standard |
|||
| SD007 | Unibiotest | 0.5ug/mL | 607 EUR |
Aflatoxin B1 [BSA] |
|||
| DAGA-009B | Creative Diagnostics | 1mg | 780 EUR |
Aflatoxin B1 [FITC] |
|||
| DAGA-009F | Creative Diagnostics | 200ul | 1365 EUR |
Aflatoxin B1 [HRP] |
|||
| DAGA-009H | Creative Diagnostics | 1mg | 1170 EUR |
Aflatoxin B1 [KLH] |
|||
| DAGA-009K | Creative Diagnostics | 1mg | 1040 EUR |
Aflatoxin B1 [OVA] |
|||
| DAGA-009O | Creative Diagnostics | 500ul | 780 EUR |
Vitamin B1 [HRP] |
|||
| DAGA-120H | Creative Diagnostics | 1mg | 1365 EUR |
Vitamin B1 [KLH] |
|||
| DAGA-120K | Creative Diagnostics | 1mg | 1365 EUR |
AMPK b1 protein |
|||
| E20-80008 | EnoGene | 20ug | 408 EUR |
Cyclin B1 protein |
|||
| E20-80120 | EnoGene | 20ug | 408 EUR |
Lamin B1 antibody |
|||
| 23038-100ul | SAB | 100ul | 390 EUR |
HBB-B1 siRNA |
|||
| 20-abx919119 | Abbexa |
|
|
SR-B1 Antibody |
|||
| abx037943-100ug | Abbexa | 100 ug | 391 EUR |
Aflatoxin B1 Antibody |
|||
| 20-abx133845 | Abbexa |
|
|
Fumonisin B1 Antibody |
|||
| 20-abx134728 | Abbexa |
|
|
From 2006 to 2019, BB-BCH contained 252,069 samples from 44,933 contributors, the entire assortment is represented by 15 various kinds of biospecimens collected from them. According to our information, the most collected and saved topography in males is head and neck (29%); in girls is breast (28%); and in youngsters is torso and limb (27%) samples. Finally, we supported nationwide and worldwide consortia and initiatives equivalent to The Cancer Genome Atlas. BB-BCH is a crucial data supply for scientific group, enabling the growth of high-quality research, with all kinds of tumor classes and excessive nationwide representativeness of Brazilian inhabitants.